Literature DB >> 1511110

[Chronic pathologies and pharmaceutical expenditure in persons over the age of 65].

X M Segade Buceta1, A Garcia Figueiras, L Cinos Ramos, X L Casais Gude, E Nieto Pol, A González Conde, C Gerpe Caamaño.   

Abstract

OBJECTIVE: For purposes of the present study of people over 65 attending a particular Health Centre, we aimed to discover and inter-relate their morbidity due to chronic illnesses, their frequency of attendance, and the total average outlay of drugs on them.
DESIGN: Descriptive crossover study. Information on the clinical histories was gathered over a one-year period (July 1990 to June '91). SITE. Within the Primary Care framework: at the Vite Health Centre in Santiago de Compostela. PATIENTS OR OTHERS PARTICIPANTS: The population aged 65 or over and with medical records in the said centre. A representative sample of this population (n = 240), obtained by systematic sampling, was worked with. MAIN
RESULTS: The sample's average age was 73.6 +/- 6.7 years. Arterial Hypertension (AHT) was the most common chronic illness. AHT, LCFA/Asthma, Hyperlipemia and digestive pathology showed significant differences between men and women. The average number of medical consultations per person per year was 11.5 +/- 0.82, with no significant differences as to sex and age. The average outlay per person per year was 27,610 pesetas +/- 38,688, with an average cost per consultation of 2,750 pesetas +/- 5,158.7. The chronic illnesses that produced a higher average total cost were heart diseases. Significant differences were shown between the number of chronic illnesses and the average total cost.
CONCLUSIONS: The presence, number and nature of chronic illnesses are the factors affecting higher outlay in medication.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511110

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  1 in total

1.  [Do we spend too much on medications? Pharmaceutical expenditures, an absolutely essential item in European countries].

Authors:  J Simó Miñan; R de Pablo González; M J Ramos Maestre; M S Gaztambide Ganuza
Journal:  Aten Primaria       Date:  2004-03-31       Impact factor: 1.137

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.